Valuation: Lexeo Therapeutics, Inc.

Market Cap 409M 353M 331M 301M 567M 39.06B 575M 3.88B 1.52B 19.57B 1.53B 1.5B 65.1B P/E 2026 *
-4.09x
P/E 2027 * -3.62x
Enterprise Value 231M 199M 187M 170M 320M 22.07B 325M 2.19B 859M 11.06B 867M 848M 36.79B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.42%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lexeo Therapeutics, Inc.

1 day+2.89%
1 week+7.56%
Current month+20.58%
1 month+6.18%
3 months-2.16%
6 months-20.70%
Current year-49.85%
1 week 4.7
Extreme 4.7
5.08
1 month 3.99
Extreme 3.99
5.08
Current year 3.99
Extreme 3.99
10.75
1 year 3.99
Extreme 3.99
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 01/01/2020
Director of Finance/CFO 50 15/08/2025
Chief Tech/Sci/R&D Officer 62 20/01/2026
Director TitleAgeSince
Director/Board Member 46 01/01/2020
Chairman 72 01/01/2021
Director/Board Member 61 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Sell

Chief Technology Officer

-22,306 0.0284%
01/07/26 Sell

Chief Operating Officer

-4,666 0.0059%
01/07/26 Sell

Chief Financial Officer

-4,641 0.0059%
Change 5-day change 1-year change 3-year change Capi.($)
+2.89%+7.56%+5.51% - 409M
+4.80%+3.44%+70.64%+109.32% 73.25B
-0.09%+14.07%+49.01%+90.42% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.24%+5.65%+56.71%+21.30% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+0.86%+6.47%+40.76%-13.56% 19.46B
+3.83%+2.65%+21.42%+557.58% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +1.57%+1.71%+50.61%+201.11% 27.75B
Weighted average by Cap. +1.93%+3.14%+54.93%+164.93%

Financials

2026 *2027 *
Net sales - -
Net income -104M -89.56M -84.02M -76.52M -144M -9.92B -146M -985M -386M -4.97B -389M -381M -16.53B -130M -112M -105M -95.92M -180M -12.43B -183M -1.23B -484M -6.23B -488M -478M -20.72B
Net Debt -178M -153M -144M -131M -246M -16.99B -250M -1.69B -661M -8.51B -667M -653M -28.32B -305M -264M -247M -225M -423M -29.19B -429M -2.9B -1.14B -14.62B -1.15B -1.12B -48.65B
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
63
Date Price Change Volume
17/08/26 $4.980 +2.89% 913,839
14/08/26 $4.840 -2.42% 676,670
13/08/26 $4.960 +1.85% 1,109,542
12/08/26 $4.870 +1.88% 1,630,273
11/08/26 $4.780 +3.24% 1,332,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.980USD
Average target price
20.30USD
Spread / Average Target
+307.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXEO Stock